ArticleEClinicalMedicine2026
Steroid, thiamine, and ascorbic acid for comatose out-of-hospital cardiac arrest survivors (STAR): a randomised, placebo-controlled, phase 2 trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04921189 (Steroid, Thiamine and Ascorbic Acid During Post-Resuscitation Period for Comatose Out-of-hospital Cardiac Arrest Survivors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Steroid, Thiamine and Ascorbic Acid During Post-Resuscitation Period for Comatose Out-of-hospital Cardiac Arrest Survivors (STAR) Trial: Multi-center, Randomized, Single-blinded, Controlled Pilot Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacologic neuroprotection for out-of-hospital cardiac arrest (OHCA) remains elusive. We evaluated whether early hydrocortisone, ascorbic acid, and thiamine reduced neuronal injury in comatose OHCA survivors. Methods: In this multicentre, placebo-controlled trial across four South Korean hospitals, comatose adult OHCA survivors undergoing targeted temperature management were randomly assigned (1:1) to intravenous hydrocortisone (100 mg), ascorbic acid (50 mg/kg), and thiamine (200 mg) every 12 h for 3 days, or placebo. Randomisation was computer-generated. Bedside clinicians were aware of treatment allocation, whereas laboratory personnel and independent outcome assessors were masked. The primary outcome was peak neuron-specific enolase (NSE) concentration, defined as the highest available value measured at 48 h or 72 h after return of spontaneous circulation. Efficacy was analysed using a modified intention-to-treat (mITT) principle, with multiple imputation for the full intention-to-treat (ITT) population. The completed trial was registered with ClinicalTrials.gov on June 4, 2021 (NCT04921189). Findings: Between Dec 31, 2021, and Dec 7, 2024, 160 participants (123 male, 37 female) were assigned (80 per group); 147 were included in the mITT analysis (74 treatment, 73 placebo). Peak NSE levels were 47·4 ng/mL (interquartile range [IQR] 22·4-262·6) in the treatment group and 53·3 ng/mL (IQR 26·6-244·2) in the placebo group (median difference -5·9 ng/mL; 95% confidence interval [CI] -34·5-40·8; p = 0·54). ITT sensitivity findings were consistent (geometric mean ratio 0·94; 95% CI 0·61-1·46; p = 0·80). At 180 days, survival (63·5% vs 69·9%) and good neurological outcome (54·1% vs 56·2%) were similar. Serious adverse events were comparable in the ITT population (52·5% vs 50·0%), with none deemed related to the study medication. Interpretation: Early administration of hydrocortisone, ascorbic acid, and thiamine did not reduce neuronal injury or improve 6-month clinical outcomes. The findings do not support empiric neuroprotective use in comatose OHCA survivors. Funding: National Research Foundation of Korea and Korea Health Technology R&D Project.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.